✦ LIBER ✦

533 - Independent radiological review of a phase III study of topotecan versus paclitaxel as second-line therapy in advanced epithelial ovarian cancer

✍ Scribed by S.J. Gwyther; M. Gore; W. ten Bokkel Huinink; S.Z. Fields; I. Hudson

Book ID: 117664781
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 378 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85046-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Trial of Topotecan, Carboplatin

Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

✍ G. Bolis; G. Scarfone; A. Villa; F. Parazzini 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 29 KB

Lapatinib Plus Paclitaxel Versus Paclita

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN--A Randomized, Phase III Study

✍ Satoh, T.; Xu, R.-H.; Chung, H. C.; Sun, G.-P.; Doi, T.; Xu, J.-M.; Tsuji, A.; O 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 335 KB

Independent radiologic review of the Gyn

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer

✍ Burger, Robert. A.; Brady, Mark F.; Rhee, Joon; Sovak, Mika A.; Kong, George; Ng 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 393 KB

915 POSTER Paclitaxel/carboplatin (TC) v

915 POSTER Paclitaxel/carboplatin (TC) versus paclitaxel/carboplatin followed by topotecan (TOP) in first line treatment of advanced ovarian cancer. mature results of a gynecologic cancer interGroup (GCIG) phase III trial of the AGO OVAR and GINECO

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

A phase II study of sabarubicin (MEN-107

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

✍ Francesco Caponigro; Pax Willemse; Roberto Sorio; Anne Floquet; Simon van Belle; 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 81 KB

Phase 3 randomised study of canfosfamide

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

✍ I. Vergote; N. Finkler; J. del Campo; A. Lohr; J. Hunter; D. Matei; J. Kavanagh; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 317 KB